AUTHORS
Elias Jabbour, MD, Yuliya Katlinskaya2, Shiya Song3, Erin Guest, MD4, Jessica Choudhry5, Federico Lussana6, Anna Torrent, MD7, Pilar Martinez Sanchez, MD, PhD8, José Rifón, MD9, Mar Tormo Sr, MD10, Hagop Kantarjian, MD11
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 Amgen Inc., Thousand Oaks, United States
3 Amgen Inc., South San Francisco, United States
4 Amgen Inc., Thousand Oaks, United States
5 Amgen Inc., Thousand Oaks, United States
6 Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy, University of Milan, Milan, Italy
7 Institut Català d'Oncologia, Institut de Recerca contra la Leucèmia Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain, Universitat Autònoma de Barcelona, Barcelona, Spain
8 Hospital Universitario 12 de Octubre, Madrid, Spain
9 Clínica Universidad de Navarra, Pamplona, Spain
10 Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain
11 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background
Neurologic events (NE) remain an important toxicity associated with cluster of differentiation (CD) 19-directed T-cell engager therapies, including subcutaneous (SC) blinatumomab, and currently lack robust biomarkers for early risk stratification. We performed an exploratory translational analysis to identify baseline immune and early pharmacodynamic biomarkers associated with subsequent higher-grade NE in adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with SC blinatumomab.
Methods
One hundred phase 1 patients from study 20180257 (NCT04521231) were included. The primary endpoint was higher-grade NE, defined as maximum on-study NE grade ≥ 2 versus ≤ 1. Baseline biomarkers included immune phenotyping, cytokines, bone marrow assessments, clinical laboratory parameters, and demographics. Early on-treatment biomarkers included cytokines, immune-cell subsets, and vital sign measurements collected approximately 6 hours after the first SC dose. Multiple machine-learning approaches (including least absolute shrinkage and selection operator [LASSO], random forest, and support vector machine [SVM]) with repeated cross-validation were used to identify recurrent predictive biomarkers and evaluate model performance.
Results
Among 100 evaluable patients, 51 (51%) experienced grade ≥ 2 NE, with most of these events occurring during Cycle 1. Patients who subsequently developed higher-grade NE demonstrated lower baseline frequencies of regulatory and activation-associated T-cell populations, including Tregs (%CD4), CD69+CD8+ T cells, and CD4 central memory T cells. Across multiple modeling approaches, tumor necrosis factor (TNF)-alpha measured approximately 6 hours after treatment initiation emerged as the most consistent early on-treatment biomarker associated with subsequent higher-grade NE. Additional recurrent immune features were also identified across multiple modeling approaches. Incorporation of early post-treatment biomarkers improved predictive performance compared with baseline features alone (ROC-AUC 0.71 vs 0.63; PR-AUC 0.70 vs 0.64). Together, these findings support a multi-stage framework in which baseline immune predisposition and early treatment-induced immune activation jointly contribute to susceptibility to higher-grade NE.
Conclusions
Baseline immune predisposition and early cytokine elevation, particularly TNF-alpha, were associated with subsequent higher-grade NE following SC blinatumomab. These findings provide insight into the biology of T-cell engager-associated NE and support future evaluation of biomarker-informed risk stratification, monitoring, and mitigation strategies.
DISCLOSURES
Elias Jabbour, MD: Ascentage - Honoraria; Pfizer - Honoraria; Takeda - Honoraria; Amgen Inc. - Honoraria; Taiho - Honoraria; Novartis - Honoraria; TGRX Pharmaceuticals - Honoraria; Adaptive Biotechnologies - Honoraria; AbbVie - Honoraria; Gilead/Kite - Honoraria; TERN - Honoraria; Autolus - Honoraria; Amgen Inc. - Research Funding; AbbVie - Research Funding; Autolus - Research Funding; Takeda - Research Funding; Pfizer - Research Funding; Taiho - Research Funding; TGRX Pharmaceuticals - Research Funding; Gilead/Kite - Research Funding; Ascentage - Research Funding; Allotera - Research Funding; Novartis - Research Funding; Adaptive Biotechnologies - Research Funding; TERN - Research Funding; Amgen Inc. - Consultancy (Includes expert testimony); Allotera - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); TGRX Pharmaceuticals - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Gilead/Kite - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Taiho - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); TERN - Consultancy (Includes expert testimony)